SPP1 promoter polymorphisms and glioma risk in a Chinese Han population

Chen, Juxiang; Wu, Qihan; Lu, Yao; Xu, Tao; Huang, Yan; Ribas, Judit; Ni, Xiaohua; Hu, Guohan; Huang, Fei; Zhou, Lei; Lu, Daru

doi:10.1038/jhg.2010.48

Cited by 17 publications

(15 citation statements)

References 29 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…A different SNP, 155_156GG was found to be significantly associated with an increased risk of glioma. Cellular assays indicated that the transcriptional activity of the SPP1 promoter containing the −155_156GG allele significantly increased in glioma cells indicating that this variant of SPP1 promoter might influence the risk of glioma by regulating promoter activity (Chen et al, 2010). …”

Section: Regulation Of Opnmentioning

confidence: 99%

Role of osteopontin in the pathophysiology of cancer

2014

View full text Add to dashboard Cite

Osteopontin (OPN) is a multifunctional cytokine that impacts cell proliferation, survival, drug resistance, invasion, and stem like behavior. Due to its critical involvement in regulating cellular functions, its aberrant expression and/or splicing is functionally responsible for undesirable alterations in disease pathologies, specifically cancer. It is implicated in promoting invasive and metastatic progression of many carcinomas. Due to its autocrine and paracrine activities OPN has been shown to be a crucial mediator of cellular cross talk and an influential factor in the tumor microenvironment. OPN has been implicated as a prognostic and diagnostic marker for several cancer types. It has also been explored as a possible target for treatment. In this article we hope to provide a broad perspective on the importance of OPN in the pathophysiology of cancer.

show abstract

Section: Regulation Of Opnmentioning

confidence: 99%

Role of osteopontin in the pathophysiology of cancer

2014

View full text Add to dashboard Cite

show abstract

“…The search strategy retrieved 40 potential relevant studies and one study was identified through references. According to the inclusion and exclusion criteria, 11 studies [ 10 , 12 , 22 – 30 ]with full text were eligible for this meta-analysis and 30 studies were excluded. The flow chart of study selection is summarized in Fig 1 .…”

Section: Resultsmentioning

confidence: 99%

Associations between the Genetic Polymorphisms of Osteopontin Promoter and Susceptibility to Cancer in Chinese Population: A Meta-Analysis

et al. 2015

View full text Add to dashboard Cite

Background and AimSeveral studies have been conducted to examine the associations between osteopontin (OPN) promoter gene SPP1 polymorphisms with human cancers in Chinese population, but the results remain inconsistent. The aim of this meta-analysis is to clarify the associations between SPP1 polymorphisms and cancer susceptibility.MethodsAll eligible case-control studies published up to March 2015 were identified by searching PubMed, Web of Science, Embase, and Cochrane Library without language restrictions. Pooled odds ratio (OR) and 95% confidence interval (95% CI) were calculated using fixed- or random-effect model.ResultsA total of 11 case-control studies were included; of those, there were eleven studies (3130 cases and 3828 controls) for -443T>C polymorphism, ten studies (3019 cases and 3615 controls) for -156G>GG polymorphism, eight studies (2258 cases and 2846 controls) for -66T>G polymorphism. Overall, no evidence indicated that the -443 T>C polymorphism was associated with cancer risk (OR = 0.93, 95%CI 0.62–1.38 for dominant model, OR = 1.06, 95%CI 0.73–1.55 for recessive model, OR = 0.88, 95%CI 0.62–1.26 for CT vs TT model, OR = 1.03, 95%CI 0.61–1.73 for CC vs TT model). While, a significantly increase risk was found for -156 G>GG polymorphism (OR = 1.22, 95%CI 1.10–1.35 for dominant model, OR = 1.25, 95%CI 1.10–1.41 for recessive model, OR = 1.18, 95%CI 1.06–1.32 for GGG vs GG model, OR = 1.35, 95%CI 1.09–1.68 for GGGG vs GG model). For -66T>G polymorphism, we found a decrease risk of cancer (OR = 0.84, 95% CI 0.71–0.98 for dominant model), but this result changed (OR = 0.93, 95% CI 0.77–1.12 for dominant model) when we excluded a study.ConclusionThis meta-analysis suggests that in Chinese population the -156G>GG polymorphism of SPP1 might be a risk factor for human cancers, while -443T>C mutation is not associated with cancer risk. For -66T>G polymorphism, it may be a protective factor for human cancers.

show abstract

“…We observed a consistently lower prevalence of G allele and GG genotype ( OPN -156G) in the DN group as compared to the T2D group. OPN -156G allele has been earlier found to have a significant association with lower diastolic function in patients with diabetes mellitus, lower risk of developing calcium urolithiasis, more rapid progression of Duchenne muscular dystrophy, susceptibility to oral squamous cell carcinoma, systemic lupus erythematosus, glioma, and T1D [ 15 , 17 , 21 , 22 , 23 , 24 , 25 ]. The increased OPN activity has been suggested to stimulate TGF-β and matrix deposition in mesangial cells, which could significantly contribute to pathophysiology of DN.…”

Section: Discussionmentioning

confidence: 99%

“…Thus, it has been suggested that OPN haplotypes instead of single nucleotide polymorphisms may be a better predictor of genetic susceptibility and will allow achieving more accurate results. A few recent studies have confirmed OPN haplotypes as modifiers of disease susceptibility in sarcoidosis, nephrolithiasis, pseudoxanthomaelasticum, gliomas, Crohn’s disease, and oral carcinogenesis [ 9 , 13 , 14 , 15 , 16 , 17 ]. In the present study we have investigated the association of three functional promoter gene polymorphisms C-443T, delG-156G, and G-66T and their haplotypes with the risk of DN in two independent cohorts of north Indian T2D patients.…”

Section: Introductionmentioning

confidence: 99%

Association between Osteopontin Promoter Gene Polymorphisms and Haplotypes with Risk of Diabetic Nephropathy

Cheema

Iyengar

Sharma

et al. 2015

JCM

View full text Add to dashboard Cite

Background: Osteopontin (OPN) C-443T promoter polymorphism has been shown as a genetic risk factor for diabetic nephropathy (DN) in type 2 diabetic patients (T2D). Methods: In the present study we investigated the association of three functional promoter gene polymorphisms C-443T, delG-156G, and G-66T and their haplotypes with the risk of DN and estimated Glomerular Filtration Rate (eGFR) in Asian Indians T2D patients using Real time PCR based Taqman assay. A total of 1165 T2D patients, belonging to two independently ascertained Indian Asian cohorts, were genotyped for three OPN promoter polymorphisms C-443T (rs11730582), delG-156G (rs17524488) and G-66T (rs28357094). Results: -156G allele and GG genotypes (delG-156G) and haplotypes G-C-G and T-C-G (G-66T, C-443T, delG-156G) were associated with decreased risk of DN and higher eGFR. Haplotype G-T-delG and T-T-delG (G-66T, C-443T, delG-156G) were identified as risk haplotypes, as shown by lower eGFR. Conclusion: This is the first study to report an association of OPN promoter gene polymorphisms; G-66T and delG-156G and their haplotypes with DN in T2D. Our results suggest an association between OPN promoter gene polymorphisms and their haplotypes with DN.

show abstract

SPP1 promoter polymorphisms and glioma risk in a Chinese Han population

Cited by 17 publications

References 29 publications

Role of osteopontin in the pathophysiology of cancer

Role of osteopontin in the pathophysiology of cancer

Associations between the Genetic Polymorphisms of Osteopontin Promoter and Susceptibility to Cancer in Chinese Population: A Meta-Analysis

Association between Osteopontin Promoter Gene Polymorphisms and Haplotypes with Risk of Diabetic Nephropathy

Contact Info

Product

Resources

About